Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting
HIV-1 replicative capacity (RC) provides a measure of within-host fitness and is determined in the context of phenotypic drug resistance testing. However it is unclear how these in-vitro measurements relate to in-vivo processes. Here we assess RCs in a clinical setting by combining a previously published machine-learning tool, which predicts RC values from partial pol sequences with genotypic and clinical data from the Swiss HIV Cohort Study. The machine-learning tool is based on a training set consisting of 65000 RC measurements paired with their corresponding partial pol sequences. We find that predicted RC values (pRCs) correlate significantly with the virus load measured in 2073 infected but drug naïve individuals. Furthermore, we find that, for 53 pairs of sequences, each pair sampled in the same infected individual, the pRC was significantly higher for the sequence sampled later in the infection and that the increase in pRC was also significantly correlated with the increase in plasma viral load and with the length of the time-interval between the sampling points. These findings indicate that selection within a patient favors the evolution of higher replicative capacities and that these in-vitro fitness measures are indicative of in-vivo HIV virus load.
Vyšlo v časopise:
Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting. PLoS Pathog 7(11): e32767. doi:10.1371/journal.ppat.1002321
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1002321
Souhrn
HIV-1 replicative capacity (RC) provides a measure of within-host fitness and is determined in the context of phenotypic drug resistance testing. However it is unclear how these in-vitro measurements relate to in-vivo processes. Here we assess RCs in a clinical setting by combining a previously published machine-learning tool, which predicts RC values from partial pol sequences with genotypic and clinical data from the Swiss HIV Cohort Study. The machine-learning tool is based on a training set consisting of 65000 RC measurements paired with their corresponding partial pol sequences. We find that predicted RC values (pRCs) correlate significantly with the virus load measured in 2073 infected but drug naïve individuals. Furthermore, we find that, for 53 pairs of sequences, each pair sampled in the same infected individual, the pRC was significantly higher for the sequence sampled later in the infection and that the increase in pRC was also significantly correlated with the increase in plasma viral load and with the length of the time-interval between the sampling points. These findings indicate that selection within a patient favors the evolution of higher replicative capacities and that these in-vitro fitness measures are indicative of in-vivo HIV virus load.
Zdroje
1. FraserCHollingsworthTDChapmanRde WolfFHanageWP 2007 Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 104 17441 17446
2. RibeiroRMQinLChavezLLLiDSelfSG 2010 Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol 84 6096 6102
3. HinkleyTMartinsJChappeyCHaddadMStawiskiE 2011 A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet 43 487 489
4. Schoeni-AffolterFLedergerberBRickenbachMRudinCGunthardHF Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 39 1176 1178
5. von WylVYerlySBoniJBurgisserPKlimkaitT 2007 Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 167 1782 1790
6. KouyosRDvon WylVYerlySBoniJRiederP 2011 Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 52 532 539
7. BennettDECamachoRJOteleaDKuritzkesDRFleuryH 2009 Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4 e4724
8. Martinez-PicadoJMartinezMA 2008 HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res 134 104 123
9. HarrisonLCastroHCanePPillayDBoothC 2010 The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 24 1917 1922
10. Quinones-MateuMEBallSCMarozsanAJTorreVSAlbrightJL 2000 A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 74 9222 9233
11. TrkolaAKusterHLeemannCRuprechtCJoosB 2003 Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J Virol 77 13146 13155
12. JoosBRiederPFischerMKusterHRusertP 2010 Association between specific HIV-1 Env traits and virologic control in vivo. Infect Genet Evol 10 365 372
13. JoosBTrkolaAFischerMKusterHRusertP 2005 Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol 79 9026 9037
14. DaarESKeslerKLWrinTPetropouloCJBatesM 2005 HIV-1 pol replication capacity predicts disease progression. AIDS 19 871 877
15. AlizonSvon WylVStadlerTKouyosRDYerlyS 2010 Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 6 e1001123
16. HollingsworthTDLaeyendeckerOShirreffGDonnellyCASerwaddaD 2010 HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog 6 e1000876
17. HechtFMHartogensisWBraggLBacchettiPAtchisonR 2010 HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 24 941 945
18. BonhoefferSFunkGAGunthardHFFischerMMullerV 2003 Glancing behind virus load variation in HIV-1 infection. Trends Microbiol 11 499 504
19. TroyerRMCollinsKRAbrahaAFraundorfEMooreDM 2005 Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 79 9006 9018
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2011 Číslo 11
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Multiple Candidate Effectors from the Oomycete Pathogen Suppress Host Plant Immunity
- The Splicing Factor Proline-Glutamine Rich (SFPQ/PSF) Is Involved in Influenza Virus Transcription
- A TNF-Regulated Recombinatorial Macrophage Immune Receptor Implicated in Granuloma Formation in Tuberculosis
- SH3 Domain-Mediated Recruitment of Host Cell Amphiphysins by Alphavirus nsP3 Promotes Viral RNA Replication